Community
Review Your Medicare Coverage Options: Open Enrollment is Through Dec. 7
By Naomi Torres
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
Naomi Torres
Naomi Torres
Reporter · Chagrin Falls, OH
Naomi Torres is a passionate community reporter with a degree in Journalism from the University of Dayton. With over four years of experience covering local stories, her focus is on uplifting voices often overlooked in mainstream media.
More from Naomi →Reporter · Sunday, November 8, 2026 at 4:00 PM · 1 min read
First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancerDeep and sustained PSA responses observed with every-six-week dosing, with 73% (11 of 15 patients)…
Up nextReview Your Medicare Coverage Options: Open Enrollment is Through Dec. 7Community · 1 min read
More Community stories
Community
Beyond the Piggy Bank: How to Build Your Child's Financial Future
By Naomi Torres
Community
Las cosas Pueden Cambiar. Revise sus Opciones de Cobertura de Medicare: La Inscripción Abierta Termina el 7 de Diciembre
By Maya Thompson
Community
La Inscripción Abierta de Medicare Termina el 7 de diciembre: Revise su Plan
By Maya Thompson